1
|
Chen T, Zhou L, Zhou Y, Zhou W, Huang H, Yin S, Xie H, Zhou L, Zheng S. HJURP Promotes Epithelial-to-Mesenchymal Transition via Upregulating SPHK1 in Hepatocellular Carcinoma. Int J Biol Sci 2019; 15:1139-1147. [PMID: 31223275 PMCID: PMC6567799 DOI: 10.7150/ijbs.30904] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Accepted: 04/07/2019] [Indexed: 12/25/2022] Open
Abstract
Holliday Junction Recognition Protein (HJURP) is involved in various cancers including hepatocellular carcinoma (HCC). Current studies have showed that HJURP is correlated with HCC proliferation. However, the role of HJURP in HCC Epithelial-to-Mesenchymal Transition remains unclear. In this study, we found that HJURP knockdown significantly reduced the migration and invasion abilities of HCC cells both in vivo and in vitro by interacting with Sphingosine kinase1 (SPHK1). Conversely, HJURP overexpression enhanced these biological abilities. Moreover, high HJURP expression is related to poor prognosis of HCC patients. In conclusion, HJURP plays an important role in tumor metastasis by upregulating SPHK1. And high HJURP expression may predict a lower disease-free survival rate and higher possibility of microvascular invasion in HCC patients.
Collapse
Affiliation(s)
- Tianchi Chen
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Zhejiang university, Hangzhou, China
| | - Lingfeng Zhou
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Zhejiang university, Hangzhou, China
| | - Yuan Zhou
- NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Zhejiang university, Hangzhou, China
| | - Wuhua Zhou
- NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Zhejiang university, Hangzhou, China
| | - Hechen Huang
- NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Zhejiang university, Hangzhou, China
| | - Shengyong Yin
- NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, China
| | - Haiyang Xie
- NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Zhejiang university, Hangzhou, China
| | - Lin Zhou
- NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Zhejiang university, Hangzhou, China
| | - Shusen Zheng
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Zhejiang university, Hangzhou, China
| |
Collapse
|
2
|
Adams DR, Tawati S, Berretta G, Rivas PL, Baiget J, Jiang Z, Alsfouk A, Mackay SP, Pyne NJ, Pyne S. Topographical Mapping of Isoform-Selectivity Determinants for J-Channel-Binding Inhibitors of Sphingosine Kinases 1 and 2. J Med Chem 2019; 62:3658-3676. [DOI: 10.1021/acs.jmedchem.9b00162] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- David R. Adams
- School of Engineering & Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, U.K
| | - Salha Tawati
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, U.K
| | - Giacomo Berretta
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, U.K
| | - Paula Lopez Rivas
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, U.K
| | - Jessica Baiget
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, U.K
| | - Zhong Jiang
- School of Engineering & Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, U.K
| | - Aisha Alsfouk
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, U.K
| | - Simon P. Mackay
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, U.K
| | - Nigel J. Pyne
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, U.K
| | - Susan Pyne
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, U.K
| |
Collapse
|
3
|
Nishino S, Yamashita H, Tamori M, Mashimo M, Yamagata K, Nakamura H, Murayama T. Translocation and activation of sphingosine kinase 1 by ceramide‐1‐phosphate. J Cell Biochem 2018; 120:5396-5408. [DOI: 10.1002/jcb.27818] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Accepted: 09/12/2018] [Indexed: 12/29/2022]
Affiliation(s)
- Shohei Nishino
- Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University Chiba Japan
| | - Hisahiro Yamashita
- Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University Chiba Japan
| | - Mizuki Tamori
- Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University Chiba Japan
| | - Masato Mashimo
- Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts Kyoto Japan
| | - Kazuyuki Yamagata
- Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University Chiba Japan
- Laboratory of International Scholars in Pharmaceuticals in Systems Biology, Graduate School of Pharmaceutical Sciences, Chiba University Chiba Japan
| | - Hiroyuki Nakamura
- Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University Chiba Japan
| | - Toshihiko Murayama
- Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University Chiba Japan
| |
Collapse
|
4
|
Takahashi H, Ashikawa H, Nakamura H, Murayama T. Phosphorylation and inhibition of ceramide kinase by protein kinase C-β: Their changes by serine residue mutations. Cell Signal 2018; 54:59-68. [PMID: 30448345 DOI: 10.1016/j.cellsig.2018.11.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2018] [Revised: 11/10/2018] [Accepted: 11/14/2018] [Indexed: 01/07/2023]
Abstract
Ceramide kinase (CerK) phosphorylates ceramide to ceramide-1-phosphate (C1P), and various roles for the CerK/C1P pathway in the regulation of cellular/biological functions have been demonstrated. CerK is constitutively phosphorylated at several serine (Ser, S) residues, however, the roles of Ser residues, including their phosphorylation, in CerK activity, have not yet been elucidated in detail. Therefore, we conducted the present study to investigate this issue. In A549 cells expressing wild-type CerK, a treatment with phorbol 12-myristate 13-acetate (PMA) decreased the formation of C1P in a protein kinase C (PKC)-βI/II-mediated manner. In the Phos-tag SDS-PAGE analysis, CerK existed in its phosphorylated form and was further phosphorylated by the PMA treatment in a PKC-βI/II-mediated manner. We examined the effects of the displacement of Ser residues (72/300/340/403/408/427) in CerK by alanine (Ala, A) on its activity and phosphorylation. Triple mutations (S340/408/427A), but not a single or double mutations (S340/408A), in CerK significantly decreased the formation of C1P. PMA-induced phosphorylation levels in S340/408A- and S340/408/427A-CerK were significantly and maximally reduced, respectively, but were similar in CerK with a single mutation and wild-type CerK. Ser residue mutations tested, including six mutations, did not affect PMA-induced decreases in C1P formation more than expected. Treatments with the protein phosphatase inhibitors, okadaic acid and cyclosporine A, decreased the formation of C1P. These results demonstrated that the activity of CerK was regulated in a phosphorylation-dependent manner in cells.
Collapse
Affiliation(s)
- Hiromasa Takahashi
- Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba 260-8675, Japan
| | - Hitomi Ashikawa
- Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba 260-8675, Japan
| | - Hiroyuki Nakamura
- Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba 260-8675, Japan.
| | - Toshihiko Murayama
- Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba 260-8675, Japan
| |
Collapse
|
5
|
Alshaker H, Srivats S, Monteil D, Wang Q, Low CMR, Pchejetski D. Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors. Breast Cancer Res Treat 2018; 172:33-43. [PMID: 30043096 PMCID: PMC6208908 DOI: 10.1007/s10549-018-4900-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Accepted: 07/19/2018] [Indexed: 11/29/2022]
Abstract
Purpose Sphingosine kinase 1 (SK1) is a protooncogenic enzyme expressed in many human tumours and is associated with chemoresistance and poor prognosis. It is a potent therapy target and its inhibition chemosensitises solid tumours. Despite recent advances in SK1 inhibitors synthesis and validation, their clinical safety and chemosensitising options are not well described. In this study, we have designed, synthesised and tested a new specific SK1 inhibitor with a low toxicity profile. Methods Field template molecular modelling was used for compound design. Lead compounds were tested in cell and mouse cancer models. Results Field template analysis of three known SK1 inhibitors, SKI-178, 12aa and SK1-I, was performed and compound screening identified six potential new SK1 inhibitors. SK1 activity assays in both cell-free and in vitro settings showed that two compounds were effective SK1 inhibitors. Compound SK-F has potently decreased cancer cell viability in vitro and sensitised mouse breast tumours to docetaxel (DTX) in vivo, without significant whole-body toxicity. Conclusion Through field template screening, we have identified a new SK1 inhibitor, SK-F, which demonstrated antitumour activity in vitro and in vivo without overt toxicity when combined with DTX. Electronic supplementary material The online version of this article (10.1007/s10549-018-4900-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Heba Alshaker
- School of Medicine, University of East Anglia, 2.53 BCRE, Norwich Research Park, Norwich, NR47UQ, UK. .,Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan.
| | - Shyam Srivats
- Department of Surgery and Cancer, Imperial College London, London, UK
| | - Danielle Monteil
- Department of Surgery and Cancer, Imperial College London, London, UK
| | - Qi Wang
- School of Medicine, University of East Anglia, 2.53 BCRE, Norwich Research Park, Norwich, NR47UQ, UK
| | | | - Dmitri Pchejetski
- School of Medicine, University of East Anglia, 2.53 BCRE, Norwich Research Park, Norwich, NR47UQ, UK.
| |
Collapse
|
6
|
Kharel Y, Agah S, Huang T, Mendelson AJ, Eletu OT, Barkey-Bircann P, Gesualdi J, Smith JS, Santos WL, Lynch KR. Saccharomyces cerevisiae as a platform for assessing sphingolipid lipid kinase inhibitors. PLoS One 2018; 13:e0192179. [PMID: 29672528 PMCID: PMC5908134 DOI: 10.1371/journal.pone.0192179] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Accepted: 01/17/2018] [Indexed: 12/05/2022] Open
Abstract
Successful medicinal chemistry campaigns to discover and optimize sphingosine kinase inhibitors require a robust assay for screening chemical libraries and for determining rank order potencies. Existing assays for these enzymes are laborious, expensive and/or low throughput. The toxicity of excessive levels of phosphorylated sphingoid bases for the budding yeast, Saccharomyces cerevisiae, affords an assay wherein inhibitors added to the culture media rescue growth in a dose-dependent fashion. Herein, we describe our adaptation of a simple, inexpensive, and high throughput assay for assessing inhibitors of sphingosine kinase types 1 and 2 as well as ceramide kinase and for testing enzymatic activity of sphingosine kinase type 2 mutants. The assay was validated using recombinant enzymes and generally agrees with the rank order of potencies of existing inhibitors.
Collapse
Affiliation(s)
- Yugesh Kharel
- Departments of Pharmacology, University of Virginia, Charlottesville, Virginia, United States of America
| | - Sayeh Agah
- Departments of Pharmacology, University of Virginia, Charlottesville, Virginia, United States of America
| | - Tao Huang
- Departments of Pharmacology, University of Virginia, Charlottesville, Virginia, United States of America
| | - Anna J. Mendelson
- Departments of Pharmacology, University of Virginia, Charlottesville, Virginia, United States of America
| | - Oluwafunmilayo T. Eletu
- Departments of Pharmacology, University of Virginia, Charlottesville, Virginia, United States of America
| | - Peter Barkey-Bircann
- Departments of Pharmacology, University of Virginia, Charlottesville, Virginia, United States of America
| | - James Gesualdi
- Departments of Pharmacology, University of Virginia, Charlottesville, Virginia, United States of America
| | - Jeffrey S. Smith
- Biochemistry & Molecular Genetics, University of Virginia, Charlottesville, Virginia, United States of America
| | - Webster L. Santos
- Department of Chemistry and VT Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia, United States of America
| | - Kevin R. Lynch
- Departments of Pharmacology, University of Virginia, Charlottesville, Virginia, United States of America
- * E-mail:
| |
Collapse
|
7
|
Fan Z, Jiang H, Wang Z, Qu J. Atorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-β1 by attenuating the upregulation of SphK1. Oncol Rep 2016; 36:1016-22. [PMID: 27349500 DOI: 10.3892/or.2016.4897] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2016] [Accepted: 03/17/2016] [Indexed: 11/06/2022] Open
Abstract
Statins are the most effective drugs used in the reduction of intracellular synthesis of cholesterol. Numerous studies have confirmed that statins reduce the risk of multiple types of cancers. Statin use in cancer patients is associated with reduced cancer-related mortality. Epithelial-to-mesenchymal transition (EMT), a complicated process programmed by multiple genes, is an important mechanism of cancer metastasis. We explored the effect and mechanism of atorvastatin on the EMT process in A549 cells by establishing an EMT model in vitro induced by TGF-β1, and evaluated the effects of atorvastatin on the lower signaling pathway of TGF-β1 stimulation. Our results showed that atorvastatin partially inhibited the EMT process, and inhibited cell migration and actin filament remodeling. Transcriptional upregulation of ZEB1 and protein sphingosine kinase 1 (SphK1) induced by TGF-β1 was also suppressed. SphK1 plasmid transient transfection strengthened the EMT process induced by TGF-β1 in the presence of atorvastatin. Our experiments confirmed that atorvastatin can partially inhibit the EMT process of non-small cell lung cancer cells induced by TGF-β1 by attenuating the upregulation of SphK1.
Collapse
Affiliation(s)
- Zhiqiang Fan
- Department of Pulmonary Medicine, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, P.R. China
| | - Handong Jiang
- Department of Pulmonary Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, P.R. China
| | - Zili Wang
- Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, P.R. China
| | - Jieming Qu
- Department of Pulmonary Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China
| |
Collapse
|
8
|
DeYonker NJ, Webster CE. A Theoretical Study of Phosphoryl Transfers of Tyrosyl-DNA Phosphodiesterase I (Tdp1) and the Possibility of a "Dead-End" Phosphohistidine Intermediate. Biochemistry 2015; 54:4236-47. [PMID: 26121557 DOI: 10.1021/acs.biochem.5b00396] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Tyrosyl-DNA phosphodiesterase I (Tdp1) is a DNA repair enzyme conserved across eukaryotes that catalyzes the hydrolysis of the phosphodiester bond between the tyrosine residue of topoisomerase I and the 3'-phosphate of DNA. Atomic level details of the mechanism of Tdp1 are proposed and analyzed using a fully quantum mechanical, geometrically constrained model. The structural basis for the computational model is the vanadate-inhibited crystal structure of human Tdp1 (hTdp1, Protein Data Bank entry 1RFF ). Density functional theory computations are used to acquire thermodynamic and kinetic data along the catalytic pathway, including the phosphoryl transfer and subsequent hydrolysis. Located transition states and intermediates along the reaction coordinate suggest an associative phosphoryl transfer mechanism with five-coordinate phosphorane intermediates. Similar to both theoretical and experimental results for phospholipase D, the proposed mechanism for hTdp1 also includes the thermodynamically favorable possibility of a four-coordinate phosphohistidine "dead-end" product.
Collapse
Affiliation(s)
- Nathan J DeYonker
- ‡Department of Chemistry, The University of Memphis, 213 Smith Chemistry Building, Memphis, Tennessee 38152, United States
| | - Charles Edwin Webster
- †Department of Chemistry, Mississippi State University, Mississippi State, Mississippi 39762, United States.,‡Department of Chemistry, The University of Memphis, 213 Smith Chemistry Building, Memphis, Tennessee 38152, United States
| |
Collapse
|